“MCLA-129 is an extremely active drug in EGFRm NSCLC and we’re scheduling a targeted investment decision To judge MCLA-129 in combination with chemotherapy, which we hope to start out early in 2024,” stated Invoice Lundberg M.D., President, Chief Government Officer of Merus. “We are in the fortunate position to have https://togeldanatoto98754.designi1.com/50575498/asia129-an-overview